- Update to our [FDA-Approved Oncology Therapies](https://beta.oncokb.org/oncology-therapies) page
- Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration

| Gene  | Mutation            | Cancer Type                | Level-associated Drug(s) in OncoKB™                                                                                                                                | Previous Level | Updated Level | Evidence                                                                                                                     |
| :---- | :------------------ | :------------------------- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- |
| FGFR1 | Fusions             | Pancreatic Cancer          | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/)          |
| FGFR2 | Fusions             | Pancreatic Cancer          | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/)          |
| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib, Lirafugratinib (Level 4\) | 4              | 2             | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |

- Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene | Mutation | Cancer Type       | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKB™                              | Evidence                                                                                                                                                                                                                                                                                    |
| :---- | :--- | :------- | :---------------- | :---------------------------------- | :---------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| 1     | BRAF | V600E    | Colorectal Cancer | Encorafenib \+ Cetuximab (Level 1\) | Encorafenib \+ Cetuximab \+ FOLFOX Regimen (Level 1\) | [FDA approval of encorafenib with cetuximab and mFOLFOX6](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf); PMID: [39863775](https://pubmed.ncbi.nlm.nih.gov/39863775/) |

####

- Addition of 8 new genes:
  - ALOX5
  - APEX1
  - CBLB
  - DHX15
  - POLH
  - RPS6KB1
  - TACSTD2
  - WEE1
